Department of Surgery, Kushiro City General Hospital, 1-12 Shunkodai, Kushiro, Hokkaido, 085-0822, Japan.
Department of Emergency Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
World J Emerg Surg. 2023 Mar 30;18(1):27. doi: 10.1186/s13017-023-00497-5.
The occurrence of massive haemorrhages in various emergency situations increases the need for blood transfusions and increases the risk of mortality. Fibrinogen concentrate (FC) use may increase plasma fibrinogen levels more rapidly than fresh-frozen product or cryoprecipitate use. Previous several systematic reviews and meta-analyses have not effectively demonstrated FC efficacy in significantly improving the risk of mortality and reducing transfusion requirements. In this study, we investigated the use of FC for haemorrhages in emergency situations.
In this systematic review and meta-analysis, we included controlled trials, but excluded randomized controlled trials (RCTs) in elective surgeries. The study population consisted of patients with haemorrhages in emergency situations, and the intervention was emergency supplementation of FC. The control group was administered with ordinal transfusion or placebo. The primary and secondary outcomes were in-hospital mortality and the amount of transfusion and thrombotic events, respectively. The electronic databases searched included MEDLINE (PubMed), Web of Science, and the Cochrane Central Register of Controlled Trials.
Nine RCTs in the qualitative synthesis with a total of 701 patients were included. Results showed a slight increase in in-hospital mortality with FC treatment (RR 1.24, 95% CI 0.64-2.39, p = 0.52) with very low certainty of the evidence. There was no reduction in the use of red blood cells (RBC) transfusion in the first 24 h after admission with FC treatment (mean difference [MD] 0.0 Unit in the FC group, 95% CI - 0.99-0.98, p = 0.99) with very low certainty of the evidence. However, the use of fresh-frozen plasma (FFP) transfusion significantly increased in the first 24 h after admission with FC treatment (MD 2.61 Unit higher in the FC group, 95% CI 0.07-5.16, p = 0.04). The occurrence of thrombotic events did not significantly differ with FC treatment.
The present study indicates that the use of FC may result in a slight increase in in-hospital mortality. While FC did not appear to reduce the use of RBC transfusion, it likely increased the use of FFP transfusion and may result in a large increase in platelet concentrate transfusion. However, the results should be interpreted cautiously due to the unbalanced severity in the patient population, high heterogeneity, and risk of bias.
在各种紧急情况下发生大量出血会增加输血需求,并增加死亡率。纤维蛋白原浓缩物(FC)的使用可能会比新鲜冷冻产品或冷沉淀更快地增加血浆纤维蛋白原水平。以前的几项系统评价和荟萃分析并未有效证明 FC 在显著降低死亡率和减少输血需求方面的疗效。在本研究中,我们调查了 FC 在紧急情况下出血的应用。
在这项系统评价和荟萃分析中,我们纳入了对照试验,但排除了择期手术中的随机对照试验(RCT)。研究人群包括紧急情况下出血的患者,干预措施是紧急补充 FC。对照组给予常规输血或安慰剂。主要和次要结局分别为住院死亡率和输血量以及血栓事件。电子数据库检索包括 MEDLINE(PubMed)、Web of Science 和 Cochrane 对照试验中心注册库。
定性综合分析中纳入了 9 项 RCT,共 701 例患者。结果表明,FC 治疗的住院死亡率略有增加(RR 1.24,95%CI 0.64-2.39,p=0.52),证据确定性非常低。FC 治疗组在入院后 24 小时内的红细胞(RBC)输血量没有减少(FC 组的平均差值[MD]为 0.0 单位,95%CI-0.99-0.98,p=0.99),证据确定性非常低。然而,FC 治疗组在入院后 24 小时内的新鲜冷冻血浆(FFP)输血量显著增加(FC 组高 2.61 单位,95%CI 0.07-5.16,p=0.04)。血栓事件的发生与 FC 治疗无显著差异。
本研究表明,FC 的使用可能导致住院死亡率略有增加。虽然 FC 似乎没有减少 RBC 输血的使用,但它可能增加了 FFP 输血的使用,并可能导致血小板浓缩物输血大量增加。然而,由于患者人群的严重程度不平衡、高度异质性和偏倚风险,结果应谨慎解释。